BioSpace News Archive

Zealand Pharma Announces Voluntary Delisting of American DepositaryShares from the U.S.-Based Nasdaq Global Select Market

Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, reported financial and operating results for the second quarter and first half of 2022.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), today announced that management will present a corporate overview at the Canaccord Genuity 42nd Annual Growth Conference being held in Boston, MA, from August 8-11, 2022.

Eargo, Inc., a medical device company on a mission to improve hearing health, reported its financial results for the second quarter ended June 30, 2022.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, provided a corporate update and reported financial results for the second quarter of 2022.

Mersana Therapeutics, Inc. (NASDAQ: MRSN), today provided a business update and reported financial results for the second quarter ended June 30, 2022.

Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, announced financial results and operational highlights for the second quarter ended June 30, 2022.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its second quarter 2022 financial results and business highlights.

AnaptysBio, Inc., a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, reported operating results for the second quarter ended June 30, 2022 and provided pipeline updates.

Athersys, Inc. (Nasdaq: ATHX) announces today results of a radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI), a Department of Defense research laboratory under the leadership of the Uniformed Services University of the Health Sciences, that showed intravenous MultiStem® (invimestrocel) administration provided benefit in an animal model of acute radiation syndrome (ARS).